Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-to Enhance CD8+ Cytolytic T Cell Responses

Immunity

Volumn 44, Issue 2, 2016, Pages 274-286

  Taylor, Alison ^a   Harker, James A ^b   Chanthong, Kittiphat ^a   Stevenson, Philip G ^a,c   Zuniga, Elina I ^b   Rudd, Christopher E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3-(3-CHLORO-4-HYDROXYPHENYLAMINO)-4-(4-NITROPHENYL)-1H-PYRROLE-2,5-DIONE; AMINOPHENOL DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; MALEIMIDE DERIVATIVE; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; SMALL INTERFERING RNA; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HERPES VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; METABOLISM; MOUSE; PHYSIOLOGY; RHADINOVIRUS; VIROLOGY; VIRUS LOAD;

AMINOPHENOLS; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HERPESVIRIDAE INFECTIONS; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALEIMIDES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; RHADINOVIRUS; RNA, SMALL INTERFERING; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD;

EID: 84958625481     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.01.018     Document Type: Article

References (91)

1. Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., Honjo T. Expression of the PD-antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 1996, 8:765-772.
2. Agnellini P., Wolint P., Rehr M., Cahenzli J., Karrer U., Oxenius A. Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. Proc. Natl. Acad. Sci. USA 2007, 104:4565-4570.
3. Ahmed R., Salmi A., Butler L.D., Chiller J.M., Oldstone M.B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 1984, 160:521-540.
4. Anderson A.C., Lord G.M., Dardalhon V., Lee D.H., Sabatos-Peyton C.A., Glimcher L.H., Kuchroo V.K. T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur. J. Immunol. 2010, 40:859-866.
5. Appleman L.J., Berezovskaya A., Grass I., Boussiotis V.A. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J. Immunol. 2000, 164:144-151.
6. Barber E.K., Dasgupta J.D., Schlossman S.F., Trevillyan J.M., Rudd C.E. The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex. Proc. Natl. Acad. Sci. USA 1989, 86:3277-3281.
7. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
8. Beals C.R., Sheridan C.M., Turck C.W., Gardner P., Crabtree G.R. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997, 275:1930-1934.
9. Beurel E., Yeh W.I., Michalek S.M., Harrington L.E., Jope R.S. Glycogen synthase kinase-is an early determinant in the differentiation of pathogenic Th17 cells. J. Immunol. 2011, 186:1391-1398.
10. Blattman J.N., Wherry E.J., Ha S.J., van der Most R.G., Ahmed R. Impact of epitope escape on PD-expression and CD8 T-cell exhaustion during chronic infection. J. Virol. 2009, 83:4386-4394.
11. Borrow P., Evans C.F., Oldstone M.B. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J. Virol. 1995, 69:1059-1070.
12. Brooks D.G., Ha S.J., Elsaesser H., Sharpe A.H., Freeman G.J., Oldstone M.B. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl. Acad. Sci. USA 2008, 105:20428-20433.
13. Burgess K.E., Odysseos A.D., Zalvan C., Druker B.J., Anderson P., Schlossman S.F., Rudd C.E. Biochemical identification of a direct physical interaction between the CD4:p56lck and Ti(TcR)/CD3 complexes. Eur. J. Immunol. 1991, 21:1663-1668.
14. Chan A.C., Iwashima M., Turck C.W., Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992, 71:649-662.
15. Chemnitz J.M., Parry R.V., Nichols K.E., June C.H., Riley J.L. SHP-and SHP-associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 2004, 173:945-954.
16. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee Cox L., et al. Selective small molecule inhibitors of glycogen synthase kinase-modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7:793-803.
17. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001, 2:769-776.
18. Cohen P., Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 2004, 3:479-487.
19. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., et al. PD-expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
20. de Lima B.D., May J.S., Stevenson P.G. Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. J. Virol. 2004, 78:5103-5112.
21. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 1999, 5:1365-1369.
22. Evans A., Riva A., Cooksley H., Phillips S., Puranik S., Nathwani A., Brett S., Chokshi S., Naoumov N.V. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology 2008, 48:759-769.
23. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 2001, 359:1-16.
24. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., et al. Engagement of the PD-immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
25. Freeman G.J., Wherry E.J., Ahmed R., Sharpe A.H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-ligand blockade. J. Exp. Med. 2006, 203:2223-2227.
26. Glimcher L.H. Trawling for treasure: tales of T-bet. Nat. Immunol. 2007, 8:448-450.
27. Grakoui A., John Wherry E., Hanson H.L., Walker C., Ahmed R. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J. Hepatol. 2006, 45:468-472.
28. Ha S.J., Mueller S.N., Wherry E.J., Barber D.L., Aubert R.D., Sharpe A.H., Freeman G.J., Ahmed R. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J. Exp. Med. 2008, 205:543-555.
29. Harker J.A., Lewis G.M., Mack L., Zuniga E.I. Late interleukin-escalates T follicular helper cell responses and controls a chronic viral infection. Science 2011, 334:825-829.
30. + T cell responses and viral control during chronic infection. Immunity 2013, 39:548-559.
31. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 2003, 100:4712-4717.
32. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
33. Husain S.M., Usherwood E.J., Dyson H., Coleclough C., Coppola M.A., Woodland D.L., Blackman M.A., Stewart J.P., Sample J.T. Murine gammaherpesvirus M2 gene is latency-associated and its protein a target for CD8(+) T lymphocytes. Proc. Natl. Acad. Sci. USA 1999, 96:7508-7513.
34. Ishida M., Iwai Y., Tanaka Y., Okazaki T., Freeman G.J., Minato N., Honjo T. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 2002, 84:57-62.
35. Kaidanovich-Beilin O., Eldar-Finkelman H. Peptides targeting protein kinases: strategies and implications. Physiology (Bethesda) 2006, 21:411-418.
36. Kanhere A., Hertweck A., Bhatia U., Gökmen M.R., Perucha E., Jackson I., Lord G.M., Jenner R.G. T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. Nat. Commun. 2012, 3:1268.
37. Kao C., Oestreich K.J., Paley M.A., Crawford A., Angelosanto J.M., Ali M.A., Intlekofer A.M., Boss J.M., Reiner S.L., Weinmann A.S., Wherry E.J. Transcription factor T-bet represses expression of the inhibitory receptor PD-and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 2011, 12:663-671.
38. Keir M.E., Freeman G.J., Sharpe A.H. PD-regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J. Immunol. 2007, 179:5064-5070.
39. Kinter A.L., Godbout E.J., McNally J.P., Sereti I., Roby G.A., O'Shea M.A., Fauci A.S. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-and its ligands. J. Immunol. 2008, 181:6738-6746.
40. Kroner A., Mehling M., Hemmer B., Rieckmann P., Toyka K.V., Mäurer M., Wiendl H. A PD-polymorphism is associated with disease progression in multiple sclerosis. Ann. Neurol. 2005, 58:50-57.
41. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., et al. PD-L2 is a second ligand for PD-and inhibits T cell activation. Nat. Immunol. 2001, 2:261-268.
42. Li C., Li W., Xiao J., Jiao S., Teng F., Xue S., Zhang C., Sheng C., Leng Q., Rudd C.E., et al. ADAP and SKAP55 deficiency suppresses PD-expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol. Med. 2015, 7:754-769.
43. Lu P., Youngblood B.A., Austin J.W., Mohammed A.U., Butler R., Ahmed R., Boss J.M. Blimp-represses CD8 T cell expression of PD-using a feed-forward transcriptional circuit during acute viral infection. J. Exp. Med. 2014, 211:515-527.
44. Macián F., López-Rodríguez C., Rao A. Partners in transcription: NFAT and AP-1. Oncogene 2001, 20:2476-2489.
45. + T cells. Immunity 2015, 42:265-278.
46. Masuda E.S., Imamura R., Amasaki Y., Arai K., Arai N. Signalling into the T-cell nucleus: NFAT regulation. Cell. Signal. 1998, 10:599-611.
47. Mathieu M., Cotta-Grand N., Daudelin J.F., Thébault P., Labrecque N. Notch signaling regulates PD-expression during CD8(+) T-cell activation. Immunol. Cell Biol. 2013, 91:82-88.
48. McDermott D.S., Varga S.M. Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think. J. Immunol. 2011, 187:5568-5576.
49. Milho R., Smith C.M., Marques S., Alenquer M., May J.S., Gillet L., Gaspar M., Efstathiou S., Simas J.P., Stevenson P.G. In vivo imaging of murid herpesvirus-infection. J. Gen. Virol. 2009, 90:21-32.
50. Neal J.W., Clipstone N.A. Glycogen synthase kinase-inhibits the DNA binding activity of NFATc. J. Biol. Chem. 2001, 276:3666-3673.
51. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N., Honjo T. Autoimmune dilated cardiomyopathy in PD-receptor-deficient mice. Science 2001, 291:319-322.
52. Oestreich K.J., Yoon H., Ahmed R., Boss J.M. NFATc1 regulates PD-expression upon T cell activation. J. Immunol. 2008, 181:4832-4839.
53. Ohteki T., Parsons M., Zakarian A., Jones R.G., Nguyen L.T., Woodgett J.R., Ohashi P.S. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J. Exp. Med. 2000, 192:99-104.
54. Okazaki T., Maeda A., Nishimura H., Kurosaki T., Honjo T. PD-immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA 2001, 98:13866-13871.
55. Okazaki T., Iwai Y., Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 2002, 14:779-782.
56. Palmer B.E., Neff C.P., Lecureux J., Ehler A., Dsouza M., Remling-Mulder L., Korman A.J., Fontenot A.P., Akkina R. In vivo blockade of the PD-receptor suppresses HIV-viral loads and improves CD4+ T cell levels in humanized mice. J. Immunol. 2013, 190:211-219.
57. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., Linsley P.S., Thompson C.B., Riley J.L. CTLA-and PD-receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 2005, 25:9543-9553.
58. Prasad K.V., Cai Y.C., Raab M., Duckworth B., Cantley L., Shoelson S.E., Rudd C.E. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc. Natl. Acad. Sci. USA 1994, 91:2834-2838.
59. Quigley M., Pereyra F., Nilsson B., Porichis F., Fonseca C., Eichbaum Q., Julg B., Jesneck J.L., Brosnahan K., Imam S., et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-inhibits T cell function by upregulating BATF. Nat. Med. 2010, 16:1147-1151.
60. Raab M., Wang H., Lu Y., Smith X., Wu Z., Strebhardt K., Ladbury J.E., Rudd C.E. T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity 2010, 32:541-556.
61. Rudd C.E. Adaptors and molecular scaffolds in immune cell signaling. Cell 1999, 96:5-8.
62. Rudd C.E., Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 2003, 3:544-556.
63. Rudd C.E., Trevillyan J.M., Dasgupta J.D., Wong L.L., Schlossman S.F. The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. Proc. Natl. Acad. Sci. USA 1988, 85:5190-5194.
64. Samelson L.E. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu. Rev. Immunol. 2002, 20:371-394.
65. Schroeder J.H., Bell L.S., Janas M.L., Turner M. Pharmacological inhibition of glycogen synthase kinase 3 regulates T cell development in vitro. PLoS ONE 2013, 8:e58501.
66. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2002, 2:116-126.
67. Sharpe A.H., Wherry E.J., Ahmed R., Freeman G.J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 2007, 8:239-245.
68. Smith X., Schneider H., Köhler K., Liu H., Lu Y., Rudd C.E. The chemokine CXCL12 generates costimulatory signals in T cells to enhance phosphorylation and clustering of the adaptor protein SLP-76. Sci. Signal. 2013, 6:ra65.
69. Song M., Park J.E., Park S.G., Lee H., Choi H.K., Park B.C., Ryu S.E., Kim J.H., Cho S. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem. Biophys. Res. Commun. 2009, 381:491-495.
70. Srinivasan M., Frauwirth K.A. Reciprocal NFAT1 and NFAT2 nuclear localization in CD8+ anergic T cells is regulated by suboptimal calcium signaling. J. Immunol. 2007, 179:3734-3741.
71. Staron M.M., Gray S.M., Marshall H.D., Parish I.A., Chen J.H., Perry C.J., Cui G., Li M.O., Kaech S.M. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-and survival of antiviral CD8(+) T cells during chronic infection. Immunity 2014, 41:802-814.
72. Stevenson P.G., Belz G.T., Castrucci M.R., Altman J.D., Doherty P.C. A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope. Proc. Natl. Acad. Sci. USA 1999, 96:9281-9286.
73. Takebe Y., Seiki M., Fujisawa J., Hoy P., Yokota K., Arai K., Yoshida M., Arai N. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 1988, 8:466-472.
74. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.
75. Tseng S.Y., Otsuji M., Gorski K., Huang X., Slansky J.E., Pai S.I., Shalabi A., Shin T., Pardoll D.M., Tsuchiya H. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 2001, 193:839-846.
76. Valk E., Leung R., Kang H., Kaneko K., Rudd C.E., Schneider H. T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-coreceptor. Immunity 2006, 25:807-821.
77. Veale M., Raab M., Li Z., da Silva A.J., Kraeft S.K., Weremowicz S., Morton C.C., Rudd C.E. Novel isoform of lymphoid adaptor FYN-T-binding protein (FYB-130) interacts with SLP-76 and up-regulates interleukin 2 production. J. Biol. Chem. 1999, 274:28427-28435.
78. Veillette A., Bookman M.A., Horak E.M., Samelson L.E., Bolen J.B. Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck. Nature 1989, 338:257-259.
79. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., Vanderford T.H., Chennareddi L., Silvestri G., Freeman G.J., et al. Enhancing SIV-specific immunity in vivo by PD-blockade. Nature 2009, 458:206-210.
80. Virgin H.W., Wherry E.J., Ahmed R. Redefining chronic viral infection. Cell 2009, 138:30-50.
81. Wacker M.J., Godard M.P. Analysis of one-step and two-step real-time RT-PCR using SuperScript III. J. Biomol. Tech. 2005, 16:266-271.
82. Weiss A., Littman D.R. Signal transduction by lymphocyte antigen receptors. Cell 1994, 76:263-274.
83. West E.E., Jin H.T., Rasheed A.U., Penaloza-Macmaster P., Ha S.J., Tan W.G., Youngblood B., Freeman G.J., Smith K.A., Ahmed R. PD-L1 blockade synergizes with IL-therapy in reinvigorating exhausted T cells. J. Clin. Invest. 2013, 123:2604-2615.
84. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
85. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., Subramaniam S., Blattman J.N., Barber D.L., Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
86. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
87. Wood J.E., Schneider H., Rudd C.E. TcR and TcR-CD28 engagement of protein kinase B (PKB/AKT) and glycogen synthase kinase-(GSK-3) operates independently of guanine nucleotide exchange factor VAV-1. J. Biol. Chem. 2006, 281:32385-32394.
88. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9:2431-2438.
89. Xiao G., Deng A., Liu H., Ge G., Liu X. Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. Proc. Natl. Acad. Sci. USA 2012, 109:15419-15424.
90. Yokosuka T., Takamatsu M., Kobayashi-Imanishi W., Hashimoto-Tane A., Azuma M., Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 2012, 209:1201-1217.
91. Zinselmeyer B.H., Heydari S., Sacristán C., Nayak D., Cammer M., Herz J., Cheng X., Davis S.J., Dustin M.L., McGavern D.B. PD-promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 2013, 210:757-774.